参考文献/References:
[1] Kleinau G,Mueller S,Jaeschke H,et al. Defining structural and functional dimensions of the extracellular thyrotropin receptor region[J]. J Biol Chem,2011,286（25）：22622-22631.
[2] Kleinau G,Hoyer I,Kreuchwig A,et al. From molecular details of the interplay between transmembrane helices of the thyrotropin receptor to general aspects of signal transduction in family a G-protein-coupled receptors （GPCRs） [J]. J Biol Chem,2011,286（29）：25859-25871.
[3] Zhang L,Baker G,Janus D,et al. Biological effects of thy-rotropin receptor activation on human orbital preadipocytes[J]. Invest Ophthalmol Vis Sci,2006,47（12）：5197-5203.
[4] Douglas RS,Afifiyan NF,Hwang CJ,et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy[J]. J Clin Endocrinol Metab,2010,95（1）：430-438.
[5] Kumar S,Schiefer R,Coenen MJ,et al. A stimulatory thy-rotropin receptor antibody（M22） and thyrotropin increase in-terleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts[J]. Thyroid,2010,20（1）：59-65.
[6] Lehmann GM,Garcia-Bates TM,Smith TJ,et al. Regulation of lymphocyte function by PPARgamma：Relevance to thyroid eye disease-related inflammation[J].PPAR Res,2008,2008：895901.
[7] Latif R,Morshed SA,Zaidi M,et al. The thyroid-stimulating hormone receptor：impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimer-ization,cleavage,and signaling[J] . Endocrinol Metab Clin North Am,2009,38（2）：319-341,viii.
[8] Allen MD,Neumann S,Gershengorn MC.Occupancy of both sites on the thyrotropin（TSH） receptor dimer is necessary for phosphoinositide signaling[J]. FASEB J,2011,25（10）：3687-3694.
[9] van Zeijl CJ,van Koppen CJ,Surovtseva OV,et al. Complete inhibition of rhTSH-,Graves' disease IgG-,and M22-induced cAMP production in differentiated orbital fibroblasts by a low-molecular-weight TSHR antagonist[J]. J Clin Endocrinol Metab,2012,97（5）：E781-E785.
[10] van Zeijl CJ,Fliers E,van Koppen CJ,et al. Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophos-phate signaling pathways[J]. Thyroid,2011,21（2）：169-176.
[11] van Zeijl CJ,Fliers E,van Koppen CJ,et al.Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglob-ulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients[J]. Thyroid,2010,20（5）：535-544.
[12] Zhang L,Bowen T,Grennan-Jones F,et al. Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction[J]. J Biol Chem,2009,284（39）：26447-26455.
[13] Kumar S,Nadeem S,Stan MN,et al. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy[J].J Mol Endocrinol,2011,46（3）：155-163.
[14] Kumar S,Iyer S,Bauer H,et al. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in Graves' orbital fibroblasts：inhibition by an IGF-I receptor blocking antibody[J]. J Clin Endocrinol Metab,2012,97（5）：1681-1687.
[15] Tsui S,Naik V,Hoa N,et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease[J].J Immunol,2008,181（6）：4397-4405.
[16] Smith TJ,Hegedüs L,Douglas RS. Role of insulin-like growth factor-1 （IGF-1） pathway in the pathogenesis of Graves' orbitopathy [J]. Best Pract Res Clin Endocrinol Metab,2012,26（3）：291-302.
[17] Neumann S,Eliseeva E,McCoy JG,et al. A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor[J]. J Clin Endocrinol Metab,2011,96（2）：548-554.
[18] Neumann S,Pope A,Geras-Raaka E,et al. A drug-like antago-nist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts[J].Thyroid,2012,22（8）：839-843.
[19] Turcu AF,Kumar S,Neumann S,et al.A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy[J]. J Clin Endocrinol Metab,2013,98（5）：2153-2159.
相似文献/References:
[1]陈宁,朱云娟,陈慧,等.TSHR胞外区中间段在BALB/c小鼠体内的免疫原性研究[J].国际内分泌代谢杂志,2007,(04):267.
[2]刘雨平,罗佐杰.促甲状腺激素受体在非甲状腺组织中的表达及意义[J].国际内分泌代谢杂志,2021,41(01):10.[doi:10.3760/cma.j.cn121383-20200509-05015]
Liu Yuping,Luo Zuojie..Expression and significance of thyroid stimulating hormone receptor in extrathyroidal tissues[J].International Journal of Endocrinology and Metabolism,2021,41(02):10.[doi:10.3760/cma.j.cn121383-20200509-05015]
[3]余静雯 胡欣 叶向荣 陈彦 刘超.2021年欧洲甲状腺学会/欧洲Graves眼病专家组Graves眼病管理指南:解读与思考[J].国际内分泌代谢杂志,2022,42(04):250.[doi:10.3760/cma.j.cn121383-20211003-10002]
Yu Jingwen,Hu Xin,Ye Xiangrong,et al.Interpretation and discussion of the 2021 European Thyroid Association/European Group on Graves'Orbitopathy Guidelines for the Management of Graves' Orbitopathy[J].International Journal of Endocrinology and Metabolism,2022,42(02):250.[doi:10.3760/cma.j.cn121383-20211003-10002]
[4]谭婕 徐书杭.IL-6受体及其受体抗体在Graves眼病中的作用研究进展[J].国际内分泌代谢杂志,2023,43(05):380.[doi:10.3760/cma.j.cn121383-20220731-07068]
Tan Jie,Xu Shuhang..Update of interleukin-6 receptor and its antibody's role in Graves' orbitopathy[J].International Journal of Endocrinology and Metabolism,2023,43(02):380.[doi:10.3760/cma.j.cn121383-20220731-07068]